10,700 Shares in Mereo BioPharma Group plc (NASDAQ:MREO) Acquired by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. purchased a new position in shares of Mereo BioPharma Group plc (NASDAQ:MREO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,700 shares of the company’s stock, valued at approximately $37,000.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC boosted its stake in shares of Mereo BioPharma Group by 58.1% during the 3rd quarter. GAMMA Investing LLC now owns 10,693 shares of the company’s stock worth $44,000 after acquiring an additional 3,928 shares during the last quarter. Avanza Fonder AB purchased a new position in shares of Mereo BioPharma Group during the 4th quarter worth $69,000. Golden State Equity Partners boosted its stake in shares of Mereo BioPharma Group by 247.7% during the 4th quarter. Golden State Equity Partners now owns 22,600 shares of the company’s stock worth $79,000 after acquiring an additional 16,100 shares during the last quarter. PFG Investments LLC boosted its stake in shares of Mereo BioPharma Group by 132.0% during the 4th quarter. PFG Investments LLC now owns 39,433 shares of the company’s stock worth $138,000 after acquiring an additional 22,433 shares during the last quarter. Finally, State Street Corp purchased a new position in shares of Mereo BioPharma Group during the 3rd quarter worth $195,000. Hedge funds and other institutional investors own 62.83% of the company’s stock.

Mereo BioPharma Group Stock Down 4.0 %

MREO stock opened at $2.90 on Wednesday. Mereo BioPharma Group plc has a 12 month low of $2.80 and a 12 month high of $5.02. The company has a 50-day moving average price of $3.36 and a 200 day moving average price of $3.88.

Analysts Set New Price Targets

MREO has been the topic of several recent analyst reports. Lifesci Capital initiated coverage on shares of Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Mereo BioPharma Group in a research report on Friday, December 6th. They set a “buy” rating and a $7.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Mereo BioPharma Group to a “strong-buy” rating in a report on Sunday, December 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a report on Monday, January 13th. Four analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $7.83.

Mereo BioPharma Group Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.